Acute myeloid leukemia is the most common form of acute leukemia inadults. It is a clinically and molecularly heterogeneous disease that is curablein about only 30% of cases.Cyclic AMP response element-binding (CREB) protein is a 43 kDabasic/leucine zipper (bZIP) transcription factor .CREB regulates theexpression of a number of genes with diverse functions. CREB regulatesexpression of genes that control cell proliferation, differentiation, andsurvival suggesting that CREB plays a role in normal and neoplastichematopoiesis. Blast cells from patients with acute myeloid leukemiaexpress higher level of CREB and this elevated CREB expression may beassociated with higher incidence of relapse or persistent disease and maypredict a poor out come in patients with AML .In this study, we aimed at defining CREB expression in Egyptian denovo AML patients through an immunohisto/cytochemical technique andcorrelate this expression with the clinical presentation ,laboratory data andclinical outcome following the induction chemotherapy. This study included35 newly diagnosed cases of Acute myeloid leukemia. The present studyrevealed that expression of CREB in leukemic blast cells was detected in60% of cases. As regards the clinical response to induction chemotherapy, astatistically significant difference between the CREB negative group andthe CREB positive group was detected .From our study we can concludethat CREB expression is a potential prognostic indicator in newly diagnosedAML Egyptian patients.